GHRP-2 and Cortisol Elevation: The Trade-Off Worth Knowing
Growth hormone-releasing peptide-2 has earned a reputation as one of the most potent synthetic secretagogues in peptide research. It reliably stimulates pulsatile GH release, boosts appetite through ghrelin-mimetic activity, and has attracted considerable interest among researchers and biohackers alike. But there's a well-documented trade-off embedded in its mechanism that deserves far more attention than it typically receives.
GHRP-2 doesn't just elevate growth hormone. It also elevates cortisol — and the magnitude of that elevation, the conditions under which it occurs, and the downstream implications are all worth understanding in detail.
How GHRP-2 Stimulates GH Release
GHRP-2 (pralmorelin) is a synthetic hexapeptide that acts primarily on the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by endogenous ghrelin. Binding to GHS-R1a on somatotrophs in the anterior pituitary triggers an intracellular calcium cascade that results in GH exocytosis.
Crucially, GHRP-2 also acts at the hypothalamic level, stimulating GHRH neurons and suppressing somatostatin tone. This dual-site action — both pituitary and hypothalamic — is what makes GHRPs generally more effective than GHRH analogs alone at provoking GH secretion. Bowers et al., 1991 first characterized this synergistic mechanism, demonstrating that GHRPs amplify the natural pulsatile rhythm of GH rather than creating a flat, non-physiological elevation.
In clinical testing, GHRP-2 has been shown to produce GH peaks of 40–90 µg/L in healthy adults following intravenous administration, making it one of the most potent GH provocative agents available. Iranmanesh et al., 2004 demonstrated robust dose-dependent GH responses in both young and older adults.
The Cortisol Connection
Here is where the story gets more complicated. GHRP-2 administration consistently elevates cortisol levels, and this isn't a minor side observation — it's a reproducible, dose-dependent pharmacological effect.
Arvat et al., 1997 conducted one of the most thorough early investigations, administering GHRP-2 intravenously at doses of 1 and 2 µg/kg to healthy volunteers. They found that GHRP-2 produced significant increases in both ACTH and cortisol, with cortisol peaks occurring approximately 30–60 minutes post-injection. The magnitude of cortisol elevation was dose-dependent and, importantly, was not blocked by GH itself, confirming an independent mechanism.
Korbonits et al., 1999 further showed that GHS-R1a is expressed in the hypothalamus and pituitary corticotrophs, meaning GHRP-2 can directly stimulate the hypothalamic-pituitary-adrenal (HPA) axis. This isn't an off-target effect — it's an intrinsic part of the receptor's biology.
The cortisol response to GHRP-2 is significant enough that some researchers have proposed it as a diagnostic tool for adrenal insufficiency. Doi et al., 2006 evaluated GHRP-2 as an alternative to the insulin tolerance test (ITT) for assessing ACTH reserve, finding it to be a reliable and safer provocative agent for the HPA axis.
How Much Cortisol Are We Talking About?
Quantifying the cortisol response matters, because context separates a trivial fluctuation from a potentially meaningful physiological stressor.
In the Arvat et al., 1997 study, GHRP-2 at 1 µg/kg IV produced cortisol increases of roughly 50–100% above baseline in healthy subjects. At higher doses, the response was even more pronounced. Subcutaneous administration — the more common route in research protocols — tends to produce a somewhat attenuated but still measurable cortisol bump.
For comparison:
A single GHRP-2-induced cortisol spike is well within the physiological range the body can handle. The concern isn't a single dose — it's chronic, repeated HPA axis stimulation over weeks or months of regular use.
Why Chronic Cortisol Elevation Matters
Cortisol is catabolic, immunosuppressive, and metabolically disruptive when chronically elevated. The effects are well-characterized across decades of endocrine research (Chrousos, 2009):
The irony is not subtle. Many researchers interested in GHRP-2 are drawn to it for its potential anabolic and body-composition benefits — exactly the outcomes that chronic cortisol elevation undermines.
GHRP-2 vs. Other Secretagogues: A Cortisol Comparison
Not all GH secretagogues stimulate the HPA axis equally. This is a critical differentiator when evaluating peptide protocols.
This selectivity profile is why ipamorelin has gained favor in contexts where HPA axis activation is undesirable. Anderson et al., 2001 demonstrated that even at high doses, ipamorelin failed to produce significant cortisol or prolactin elevations — a stark contrast to GHRP-2 and hexarelin.
Does Tolerance Develop to the Cortisol Effect?
This is one of the more important open questions. Some data suggest that the cortisol response to GHRPs may attenuate with repeated dosing, while the GH response is partially preserved.
Rahim et al., 1998 observed that chronic oral administration of a GHS in elderly subjects produced diminishing ACTH and cortisol responses over several weeks, while GH responses also declined but to a lesser degree. This partial dissociation is encouraging but far from definitive.
The practical implication is that pulsatile dosing — with intentional off-periods — may help mitigate sustained HPA axis activation. However, no long-term controlled studies have specifically characterized the cortisol trajectory of chronic subcutaneous GHRP-2 use at the doses commonly discussed in biohacking communities (typically 100–300 µg, 2–3 times daily).
Practical Considerations for Researchers
For those studying GHRP-2 in research contexts, several factors modulate the cortisol response: